6 Bargain Biotech Stocks
Michael Shulman, July 10, 2009
Free Trading Guides
-
The Next Housing Crisi is About to Start -- Are You Ready to Profit?
-
#3 Cepheid (CPHD)
When my son had a huge boil under his arm, it turned out that it was filled with the killer staph, MRSA. It also turns out that my (otherwise) great doctor used a traditional lab to process the test, which took a week to determine it was MRSA. Cepheid (CPHD) manufactures the equipment and test that takes just two hours to do the same thing—and is better and cheaper than traditional tests.
CPHD wins 90%-plus of all competitive bids and its test could be available in low-tech facilities, such as doctors' offices or nursing homes, next year. The big catalyst for this stock, however, is that Medicare will stop paying for all hospital-acquired infections except MRSA in October. So institutions need a quick test if they are going to be reimbursed for treatment. The stock has fallen from $30 to $9 and change. It's worth $20-$22 to an acquirer.
Best strategy: Buy the call options.
More By This Expert
What are the five rules for constructing great short-side positions? Read on to find out.
10 Reasons to Use ETFs When Trading Options
How do investors and traders cope with a market that has fallen more than 40% in just one year and survive until greener pastures return?
The Bad News Victims of 2008 are the
New Victors of 2009
There were a lot of losing trades last year, but there were also winners for those willing to bet against conventional wisdom -- and this will be the case in 2009, too.
The 10 Dumbest Analyst Calls of 2008
This collection of calls has been easier to write than See Spot Run. My only difficulty has been restraining myself in order to not be sued, punched out or have my tires slashed.
Don't Stop 'Banking' on a Bailout
The Titanic is only just approaching the iceberg. And there aren't enough lifeboats handy for everyone who's going to need one.
